Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Stage I, II, III (T1-4, N0-3, M0)~    * No metastases to supraclavicular, contralateral hilar, or contralateral scalene lymph nodes~ * Medically inoperable or unresectable~* No pleural or pericardial effusion (except with repeated negative cytology)~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0 or 1~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 6.8 g/dL~* No hemoptysis causing a decrease of hemoglobin of 1 g/dL or more within 24 hours~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 1.25 times normal OR~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No evidence of heart failure~* No myocardial infarction within the past 6 months~* No superior vena cava syndrome~Pulmonary:~* FEV1 at least 1 L~* No pre-existing fibrotic lung disease~* No postobstructive pneumonia preventing exact delineation of tumor volume~* Diffusion capacity at least 60%~Other:~* No weight loss of more than 10% in the past 3 months~* No uncontrolled infection~* No serious medical risk factors involving any of the major organ systems that would preclude adherence to the study treatment schedule~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the chest~* Maximum length of the esophagus receiving 40 Gy no greater than 18 cm~* Maximum length of the esophagus receiving 66 Gy no greater than 12 cm~* Must limit the spinal cord dose to a maximum of 50 Gy~* Must be able to exclude 25% of the heart from the boost volume~Surgery:~* Not specified~Other:~* No other concurrent experimental medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).